Recent News

• 09.18.2025 - Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
• 09.11.2025 - Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
• 09.03.2025 - Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
• 09.02.2025 - Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 07.16.2025 - Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
• 07.15.2025 - Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Recent Filings

• 09.18.2025 - EX-99.1 EX-99.1
• 09.18.2025 - 8-K Current report
• 09.11.2025 - EX-99.1 EX-99.1
• 09.11.2025 - 8-K Current report
• 09.03.2025 - 8-K Current report
• 09.03.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.28.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]